Written in NATIONAL on 4/26/2022 2:49 p.m
The Ministry of Health (Ssa) reported that next Thursday, April 28, the vaccination registry for children under the age of 12 without comorbidities will start, but which vaccine will they use?
The Secretary of State for Prevention and Health Promotion, Hugo López Gatell, reported that they plan to use three different brands vaccinations however, for minors, this still needs to be confirmed.
For now, the epidemiologist reported that one of the candidates is the COVID-19 vaccine Pfizer and BioNTechwhich was approved for minors by the US Food and Drug Administration (FDA) last year.
The European Medicines Agency (EMA) said Pfizer’s vaccine is 90.7 percent effective in preventing symptomatic COVID-19 (although the true rate could range from 67.7 percent to 98.3 percent).
The other two vaccines that could be used in children under 12 are the Cuban. Abdala and CoronaVacby the Chinese pharmaceutical Sinovacwhich, according to López-Gatell, are also highly effective in children.
In the morning conference of President Andrés Manuel López Obrador, the official in charge of the pandemic in Mexico explained that the Abdala vaccine was delivered in Cuba to children as young as two years old.
“Cuba has achieved coverage of over 96 percent of its entire population, including children as young as two years old. We’re not currently considering 2 to 5 years, only 5 to 11, but the Abdala vaccine could be an excellent option,” he said.
abdullahthe first COVID vaccine in Latin America, is 92 percent effective and has an intramuscular administration schedule of three doses in 28 days.
He also commented that the vaccine CoronaVac It is also being considered because in other parts of the world it is used not only in people over the age of 18 but also in girls and boys.
They have been using the vaccine since the beginning of the year Sinovac in children aged 5 to 11 in the Dominican Republic and Brazil, where they deliver as much as 0.5 milligrams of the biologic, the same amount given to adults.
According to a study by the Pontifical University of Chile, the Efficacy of the Sinovac vaccine it is 64.6 percent in preventing hospital admissions and 69 percent in preventing COVID-19-related ICU admissions._With information from EFE.